Technical Analysis for GNCAQ - Genocea Biosciences Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | N/A | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
New 52 Week Closing High | Bullish | 700.00% | |
Calm After Storm | Range Contraction | 700.00% | |
Narrow Range Bar | Range Contraction | 700.00% | |
Calm After Storm | Range Contraction | 1500.00% | |
Narrow Range Bar | Range Contraction | 1500.00% | |
Calm After Storm | Range Contraction | 1500.00% | |
Narrow Range Bar | Range Contraction | 1500.00% | |
Narrow Range Bar | Range Contraction | 1500.00% | |
Narrow Range Bar | Range Contraction | 1500.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Get a Trading Sidekick!
Genocea Biosciences Inc Description
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Classification
Keywords: Medicine Medical Specialties Biopharmaceutical U.S. Bankruptcy Court Immune System Solid Tumors Immunotherapy Cell Therapy Cancer Treatments Antigen Immunotherapies T Cell Biomolecules Novel Cancer Gen 009 Gen 011 Patient's Tumor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Date | Title |
---|
Indicator | Value |
---|---|
52 Week High | 0.0064 |
52 Week Low | 0.0001 |
Average Volume | 11,579 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.0000 |
20-Day Moving Average | 0.0000 |
10-Day Moving Average | 0.0003 |
Average True Range | 0.0008 |
RSI | 0.00 |
ADX | 0.0 |
+DI | 98.9130 |
-DI | 0.0000 |
Chandelier Exit (Long, 3 ATRs) | 0.0040 |
Chandelier Exit (Short, 3 ATRs) | 0.0025 |
Upper Bollinger Bands | 0.0000 |
Lower Bollinger Band | 0.0000 |
Percent B (%b) | 0.0 |
BandWidth | 0.0000 |
MACD Line | 0.0001 |
MACD Signal Line | 0.0000 |
MACD Histogram | 0.0001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0039 | ||||
Resistance 3 (R3) | 0.0036 | 0.0026 | 0.0035 | ||
Resistance 2 (R2) | 0.0026 | 0.0020 | 0.0027 | 0.0033 | |
Resistance 1 (R1) | 0.0021 | 0.0017 | 0.0024 | 0.0024 | 0.0032 |
Pivot Point | 0.0011 | 0.0011 | 0.0012 | 0.0012 | 0.0011 |
Support 1 (S1) | 0.0006 | 0.0005 | 0.0009 | 0.0009 | 0.0000 |
Support 2 (S2) | -0.0004 | 0.0002 | -0.0003 | -0.0001 | |
Support 3 (S3) | -0.0009 | -0.0004 | -0.0003 | ||
Support 4 (S4) | -0.0007 |